Truist Financial Corp Reduces Position in Elevance Health, Inc. $ELV

Truist Financial Corp lessened its holdings in Elevance Health, Inc. (NYSE:ELV) by 27.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 155,259 shares of the company’s stock after selling 57,451 shares during the quarter. Truist Financial Corp owned approximately 0.07% of Elevance Health worth $50,167,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ELV. Vermillion & White Wealth Management Group LLC lifted its stake in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares during the last quarter. BOK Financial Private Wealth Inc. acquired a new stake in Elevance Health during the second quarter worth approximately $32,000. Glass Jacobson Investment Advisors llc lifted its position in shares of Elevance Health by 400.0% during the 2nd quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock worth $39,000 after buying an additional 80 shares during the last quarter. Motco boosted its holdings in shares of Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares in the last quarter. Finally, Trust Co. of Toledo NA OH purchased a new position in shares of Elevance Health in the 2nd quarter valued at $43,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat estimates: ELV reported $3.33 EPS vs. $3.10 consensus and revenue growth year-over-year, helped by higher premiums and strong Carelon revenues—an outcome investors often reward. Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums
• Positive Sentiment: Dividend bump: the company raised its quarterly dividend to $1.72 (annualized yield ~2.0%), a small cash-return signal that can support the share price.
• Positive Sentiment: Brokerage sentiment remains constructive: ELV retains an average “Moderate Buy” recommendation from brokers, which can underpin demand as investors digest guidance. Elevance Health, Inc. (NYSE:ELV) Given Average Recommendation of “Moderate Buy” by Brokerages
• Neutral Sentiment: Full Q4 materials and call transcript are available for investors wanting detail on membership, margins and Carelon performance; these provide context but don’t change the headline story. Elevance Q4 Slide Deck / Press Release
• Negative Sentiment: 2026 EPS guide misses Street: management set FY2026 EPS ~25.50, below the ~26.89 consensus, citing elevated medical costs—this is the primary driver of selling pressure and re-rating risk. Elevance forecasts 2026 profit below estimates on elevated medical costs (Reuters)
• Negative Sentiment: Margin and membership pressures: analysts flag medical membership declines, rising medical expenses and margin pressure that shape a weaker revenue/outlook profile for 2026. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts Shape 2026 Outlook
• Negative Sentiment: Medicare Advantage headwinds: the CMS proposed a very small 2027 MA rate increase (0.09%), a regulatory signal that intensified recent volatility and limited upside. Health Insurance Stock Could Rebound Off Historically Bullish Signal

Elevance Health Stock Performance

NYSE:ELV opened at $346.33 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. The firm has a market cap of $76.97 billion, a price-to-earnings ratio of 13.79, a price-to-earnings-growth ratio of 1.86 and a beta of 0.51. The firm’s fifty day moving average price is $351.21 and its 200 day moving average price is $328.99. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, sell-side analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.0%. Elevance Health’s dividend payout ratio (DPR) is currently 27.96%.

Wall Street Analyst Weigh In

Several research firms have issued reports on ELV. Robert W. Baird upped their price objective on shares of Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. The Goldman Sachs Group began coverage on Elevance Health in a report on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 target price for the company. Mizuho set a $413.00 price target on Elevance Health in a research note on Friday, January 9th. Wolfe Research set a $425.00 price objective on Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Elevance Health from $384.00 to $394.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 28th. Twelve analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $398.00.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.